Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Synonyms :
Class :
Brand Name :
Synonyms :
Class :
acetylsalicyclic acid: it may increase the risk of methemoglobinemia agents
acetylsalicyclic acid: it may increase the risk of methemoglobinemia agents
acetylsalicyclic acid: it may increase the risk of methemoglobinemia agents
acetylsalicyclic acid: it may increase the risk of methemoglobinemia agents
acetylsalicyclic acid: it may increase the risk of methemoglobinemia agents
may increase the risk or severity of hypertension when combined
may increase the anticoagulant effect of antiplatelet agents
may have an increased anticoagulant effect when combined with Heparin
may enhance the risk of hypoglycemia when combined with Acetylsalicylic acid
may enhance the risk of adverse effects when combined with acetylsalicylic acid
may increase the risk of hyperglycemia when combined
may increase the risk of adverse effects when combined
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
when both the drugs are combined, there might be an increase in the anticoagulant effect
it decreases the rate of elimination of pidotimod
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
antiplatelet agents increase the antiplatelet effect of abrocitinib
tenoxicam: they may increase the anticoagulant effect of Antiplatelet agents
probenecid: they may increase the anticoagulant effect of Antiplatelet agents
NSAIDS may enhance the neuroexcitatory and/or seizure-potentiating effect of quinolones
NSAIDS may enhance the neuroexcitatory and/or seizure-potentiating effect of quinolones
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
antiplatelet agents may enhance the anticoagulant effect of thrombolytic Agents
choline magnesium trisalicylate
may enhance the adverse/toxic effect of salicylates
Corticosteroids may enhance the adverse/toxic effect of nonsteroidal Anti-Inflammatory agents
Corticosteroids may enhance the adverse/toxic effect of nonsteroidal Anti-Inflammatory agents
Corticosteroids may enhance the adverse/toxic effect of nonsteroidal Anti-Inflammatory agents
Corticosteroids may enhance the adverse/toxic effect of nonsteroidal Anti-Inflammatory agents
Corticosteroids may enhance the adverse/toxic effect of nonsteroidal Anti-Inflammatory agents
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may enhance the risk of adverse effect of thrombolytic agents
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
choline magnesium trisalicylate
may enhance the adverse effect of salicylates
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
choline magnesium trisalicylate
may increase the risk of adverse effects
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
Reduced cefotiam excretion may occur when acetylsalicylic acid is administered concurrently
it may diminish the excretion rate when combined with gadofosveset, resulting in an enhanced serum level
it may enhance the risk of bleeding when combined with mitomycin
When aminophenazone is taken together with acetylsalicylic acid, there is a potential for an elevated risk or enhanced seriousness of adverse events
acetylsalicylic acid Might lead to a reduction in the rate of excretion of triethylenetetramine, potentially leading to elevated levels of serum
Combining xamoterol with Acetylsalicylic acid may elevate the risk/seriousness of hypertension
acetylsalicylic acid may reduced levobetaxolol's antihypertensive effects
levobupivacaine's rate of excretion may be reduced by acetylsalicylic acid, which might raise the serum level
Combining acetylsalicylic acid with pranlukast may cause a reduction in the acetylsalicylic acid metabolism
acetylsalicylic acid has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
When loracarbef is used together with acetylsalicylic acid, the risk or seriousness of nephrotoxicity is enhanced
When acetylsalicylic acid is used together with hexoprenaline, the potential for hypertension to occur may be elevated
When acetylsalicylic acid is used together with sertraline, the risk or seriousness of bleeding may be enhanced
It may enhance the risk of adverse effects when combined with Nonopiods
When acetylsalicylic acid is used together with fluconazole, this leads to reduction in the acetylsalicylic acid metabolism
When mometasone furoate is used together with acetylsalicylic acid, this leads to enhanced risk or seriousness of adverse outcomes
When acetylsalicylic acid is used together with cephaloglycin, this leads to increased risk or seriousness of nephrotoxicity
When melitracen is used together with acetylsalicylic acid, this leads to increased risk or seriousness of gastrointestinal bleeding
When acetylsalicylic acid is used together with abediterol, this leads to enhanced risk or seriousness of hypertension
acetylsalicylic acid has the potential to reduce the excretion rate of deferiprone, leading to an increased level of serum
When acetylsalicylic acid is used together with proglumetacin, this leads to enhanced risk or seriousness of adverse events
When bufexamac is used together with acetylsalicylic acid, this leads to a reduction in therapeutic effectiveness of acetylsalicylic acid
When acetylsalicylic acid is used together with vilanterol, this leads to enhanced risk or seriousness of hypertension
When acetylsalicylic acid is used together with benoxaprofen, this leads to enhanced risk or seriousness of adverse events
acetylsalicylic acid leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
When acetylsalicylic acid is used together with fenbufen, this leads to enhanced risk or seriousness of adverse events
acetylsalicylic acid leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
acetylsalicylic acid leads to a reduction in the rate of excretion of oxyquinoline, which leads to increased level of serum
the risk or severity of adverse effects may increase when acetylsalicylic acid is combined with alendronic acid
the excretion rate of ioxilan may be decreased by acetylsalicylic acid, potentially resulting in a rise in serum level
acetylsalicylic acid leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
the risk of adverse effects may increase when acetylsalicylic acid is combined with isoxicam
phylloquinone may decrease the excretion rate of acetylsalicylic acid, potentially leading to higher serum levels
acetylsalicylic acid may lower the excretion rate of muzolimine, potentially leading to higher serum levels
the excretion rate of mycophenolic acid may be decreased by acetylsalicylic acid, leading to a potential increase in serum levels
the excretion rate of n-acetyl tyrosine may be decreased by acetylsalicylic acid, potentially leading to higher serum levels
the excretion rate of sulbactam may be decreased by acetylsalicylic acid, potentially leading to higher serum levels
acetylsalicylic acid: it may increase the arrhythmogenic activities of lidoflazine
When acetylsalicylic acid is used together with nifenazone, this leads to enhanced risk or seriousness of adverse events
acetylsalicylic acid may enhance the antiplatelet activities of sulfinpyrazone
the efficacy of acetylsalicylic acid can be lowered when used in combination with sulindac
concomitant administration of acetylsalicylic acid with taurocholic acid may elevate the risk of adverse effects
the risk or extent of hypertension can be raised when acetylsalicylic acid is combined with doxofylline
acetylsalicylic acid coupled with isometheptene can raise the risk or degree of bp
acetylsalicylic acid: it may decrease the antihypertensive activities of phentolamine
When acetylsalicylic acid is used together with diazoxide, this leads to reduction in diazoxide’s antihypertensive effects
it may increase the antiplatelet effect of properties of antiplatelet drugs
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
antiplatelet agents may enhance the adverse/toxic effect of ibritumomab tiuxetan
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
it may enhance the antiplatelet effect of Agents with antiplatelet Properties
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may enhance the effect of antiplatelet properties
may increase the antiplatelet effect of antiplatelet agents
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may increase the antiplatelet effect of antiplatelet agents
may increase the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may decrease the tiopronin excretion rate
may have an increasingly adverse effect when combined with Apixaban
May have an increased anticoagulant effect when combined with Antiplatelet agents
may have an increasingly adverse effect when combined with Edoxaban
May have an increasingly adverse effect when combined with Antiplatelet agents
May have an increased antiplatelet effect when combined with Antiplatelet agents
may increase the toxic effect of salicylates
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
other antiplatelet agents increase the toxicity of cephalothin
it increases the effect of antiplatelet agents
it increases the toxicity of antiplatelet agents
choline magnesium trisalicylate
antiplatelet agents increase the toxicity of salicylates
other antiplatelet agents increase the toxicity of ibritumomab tiuxetan
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may increase the anti-coagulant effect of Anti-coagulants
may increase the anticoagulant effect of Anticoagulants
may increase the adverse effect of pentosan polysulfate sodium
may increase the antiplatelet effect
may have an increasingly adverse effect when combined with obinutuzumab
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the efficacy of antiplatelet agents
anagrelide: they may increase the antiplatelet effect of antiplatelet agents
pirtobrutinib: they may increase the antiplatelet effect of antiplatelet agents
prostaglandin: they may increase the antiplatelet effect of antiplatelet agents
prostaglandin: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin D analogs: they may increase the antiplatelet effect of antiplatelet agents
Vitamin B12: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Bile Acid Sequestrants: they may diminish the absorption of Antiplatelet Agent
dasabuvir: they may increase the anticoagulant effect antiplatelet agents
verteporfin: they may increase the antiplatelet effect of Agents with antiplatelet agentss
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
high nephrotoxic reactions occur when cefmetazole interacts with acetylsalicylic acid
the antihypertensive action of clonidine can be decreased with acetylsalicylic acid
hypertension severity will increase when acetylsalicylic acid is combined with etafedrine
an increase in the severity of adverse effects may be seen when acetylsalicylic acid is taken with kebuzone
an increase in the risk of adverse effects can be seen when acetylsalicylic acid is taken with mofebutazone
zuclopenthixol: they may increase the antiplatelet effect of Agents with antiplatelet properties
etravirine: they may increase the antiplatelet effect of Agents with antiplatelet agent
the hyperkalemic activity of acetylsalicylic acid may be increased
hyperkalemia can be elevated when prenylamine is combined with acetylsalicylic acid
may have a decrease in excretion when combined with acetylsalicylic acid
the risk of adverse effects may be increased
the therapeutic activity of guacetisal may be reduced
the risk of hypertension may be increased
the risk of adverse effects may be increased
the risk of hypertension, renal failure, and hypokalemia may be increased
the risk or intensity of gastrointestinal bleeding can be heightened when acetylsalicylic acid is combined with ibandronate
may intensify the negative/harmful impact of caplacizumab
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
